[Hybrid imaging in prostate cancer : Status quo and future applications]. / Hybridbildgebung beim Prostatakarzinom : Status quo und zukünftige Entwicklungen.
Radiologe
; 60(5): 386-393, 2020 May.
Article
em De
| MEDLINE
| ID: mdl-31996945
ABSTRACT
BACKGROUND:
Recently, the use of prostate-specific membrane antigen (PSMA) tracers like 68Ga-PSMA-11 in positron emission tomography (PET) have shown promising results and are helping to improve care for patients with prostate cancer (PC).PURPOSE:
In the following we review the current literature on PSMA-ligand PET, in particular with regard to the currently increasing replacement of 68Ga-PSMA ligands by 18F-labeled PSMA ligands.RESULTS:
PSMA-ligand PET is most frequently used for biochemical recurrence. Here, 68Ga-PSMA-11 PET/CT shows superior detection rates compared to conventional imaging modalities, especially in small, morphologically unsuspicious lesions, even at low PSA values. Furthermore, 68Ga-PSMA PET imaging seems to be an encouraging alternative for staging of high-risk patients, particularly in combination with multiparametric MRI.CONCLUSION:
The use of PSMA-ligand PET has revolutionized PC imaging. Thus, PSMA-ligand PET is expected to play an even greater role in PC diagnostics in the future, especially as 18F-labeled PSMA ligands are now increasingly used. However, simultaneous image analysis of PET and CT as well as a differentiated image evaluation (clinical context, knowledge of common pitfalls) is mandatory.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Imagem Multimodal
Tipo de estudo:
Prognostic_studies
Limite:
Humans
/
Male
Idioma:
De
Ano de publicação:
2020
Tipo de documento:
Article